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Abstract
The last decade has witnessed a growing appreciation 
of the fundamental role played by an early assembly 
of a diverse and balanced gut microbiota and its sub-
sequent maintenance for future health of the host. Gut 
microbiota is currently viewed as a key regulator of 
a fluent bidirectional dialogue between the gut and 
the brain (gut-brain axis). A number of preclinical 
studies have suggested that the microbiota and its 
genome (microbiome) may play a key role in neuro-
developmental and neurodegenerative disorders. 
Furthermore, alterations in the gut microbiota com-
position in humans have also been linked to a variety of 
neuropsychiatric conditions, including depression, autism 
and Parkinson’s disease. However, it is not yet clear 
whether these changes in the microbiome are causally 
related to such diseases or are secondary effects 
thereof. In this respect, recent studies in animals 
have indicated that gut microbiota transplantation can 
transfer a behavioral phenotype, suggesting that the 
gut microbiota may be a modifiable factor modulating 
the development or pathogenesis of neuropsychiatric 
conditions. Further studies are warranted to establish 
whether or not the findings of preclinical animal ex-
periments can be generalized to humans. Moreover, 
although different communication routes between 
the microbiota and brain have been identified, further 
studies must elucidate all the underlying mechanisms 
involved. Such research is expected to contribute to 
the design of strategies to modulate the gut microbiota 
and its functions with a view to improving mental 
health, and thus provide opportunities to improve the 
management of psychiatric diseases. Here, we review 
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the evidence supporting a role of the gut microbiota 
in neuropsychiatric disorders and the state of the art 
regarding the mechanisms underlying its contribution to 
mental illness and health. We also consider the stages 
of life where the gut microbiota is more susceptible to 
the effects of environmental stressors, and the possible 
microbiota-targeted intervention strategies that could 
improve health status and prevent psychiatric disorders 
in the near future. 
Key words: Microbiota; Microbiome; Dysbiosis; Brain-
gut axis; Mental health; Psychiatric conditions 
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The gut microbiota has been revealed as 
an additional regulator of the gut-brain axis, which 
may be involved in many neurodevelopmental and 
neurodegenerative disorders. The modulation of 
this axis is currently being explored, targeting the 
gut microbiota in endeavors to improve mental 
health, especially in early and late life. So far, most 
of our knowledge is based on animal trials, in which 
interventions with pro and prebiotics have shown 
promising results regarding efficacy. Nevertheless, we 
require further understanding of how the microbiota 
regulates gut-brain communication and function in 
order to establish the rationale behind microbiota-
based interventions. 
Cenit MC, Sanz Y, Codoñer-Franch P. Influence of gut microbiota 
on neuropsychiatric disorders. World J Gastroenterol 2017; 
23(30): 5486-5498  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v23/i30/5486.htm  DOI: http://dx.doi.
org/10.3748/wjg.v23.i30.5486
INTRODUCTION
Research into the influence of human genetics on 
numerous conditions, including neuropsychiatric 
disorders, has been underway for many years; 
however, the etiology of most of these conditions 
has yet to be unraveled. As in other multifactorial 
conditions, there is considerable discordance in the 
development of neuropsychiatric disorders between 
monozygotic twins, indicating that non-genetic 
factors are also involved[1,2]. Nowadays we know that 
both the human genome and the genome of the gut 
microbiota (microbiome) are essential for maintaining 
health, since the latter also plays a crucial role in 
regulating important aspects of host physiology, 
including brain development and function[3,4]. Indeed, 
different studies have reported that gut microbiota 
is able to shape brain physiology and thus behavior 
through the gut-microbiota-brain axis and have 
suggested gut microbiota as a key trigger factor in the 
development of many neuropsychiatric conditions[5]. 
Most of the neuropsychiatric disorders are considered 
as multifactorial disorders prompted by certain 
environmental factors in genetically susceptible 
individuals. However, there is a need of further work 
to elucidate the exact complex gene-environment 
interactions and gut microbiota alterations that 
precede the onset of the different neuropsychiatric 
diseases and their manifestations in order to decipher 
the etiology of the neuropsychiatric disorders. 
It is noteworthy that the microbiota is more 
“medically” accessible and modifiable than the human 
genome. This fact provides a promising opportunity for 
preventing or treating neuropsychiatric conditions[6]. 
In this respect, studies in animal models, where the 
intestinal microbiota can easily be manipulated, have 
shed light on how the microbiota may be involved 
in the development of certain mental diseases. In 
fact, different communication routes between the 
microbiota and brain have already been identified[7] 
although further studies are required to elucidate 
the underlying mechanisms. Various studies also 
indicate that the activity of the gut microbiota can 
modify the host epigenome impacting on gene 
expression[8]; furthermore, epigenetic mechanisms are 
involved in neurogenesis, neuronal plasticity, learning 
and memory, and in disorders such as depression, 
addiction, schizophrenia and cognitive dysfunction[3]. 
Consequently, it has been suggested that gut micro-
biota may be involved in the pathogenesis and risk 
of developing neuropsychiatric disorders through 
epigenetic modifications, which are highly dynamic 
and reversible[3]. Thus, it is tempting to speculate that 
modulating the microbiota and its metabolic products 
will enable us to modulate the epigenome and, 
thereby, prevent or treat mental illness. In this respect, 
metabolites produced by the microbiota from fiber 
fermentation are known to inhibit histone deacetylases 
(HDACs) and reduce inflammation through epigenetic 
modifications[9]. 
Currently it is well accepted that our gut microbiota 
is critical for brain processes such as myelination, 
neurogenesis and microglial activation and can 
effectively modulate behavior and influence psycholo­
gical processes such as mood and cognition[10]. Indeed, 
very recently gut microbiota have been shown essential 
for the maintenance of microglia in a healthy functional 
state[11], which is necessary for the prevention of neuro-
developmental and neurodegenerative disorders[12]. 
The early assembly of a well-balanced microbiota 
composition and its subsequent maintenance is 
considered crucial for human health as perturbations 
negatively impact health and increase host sus-
ceptibility to a wide variety of diseases, including 
behavioral and neuropsychiatric disorders[3,4]. In 
this respect, three critical time windows have been 
proposed including infancy, adolescence and ageing, 
when the gut microbiota is more vulnerable to external 
influence[13]. Therefore, strategies aiming to target the 
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gut microbiota might have a greater impact at those 
stages of life, i.e., newborn, adolescence and elderly 
populations. 
Many factors, including human genetics, influence 
the gut microbiota composition; therefore the mi-
crobiota constitutes a highly dynamic ecosystem, with 
high inter-individual variability[14,15] and this indeed 
hampers the understanding of the role of gut microbiota 
in the etiology and progress of neuropsychiatric 
diseases. 
Nowadays, each adult individual is believed to 
harbor a unique gut microbiota composition, as per-
sonal as a fingerprint, and certain early life events may 
be important contributors to the individual’s microbiota, 
including mode of delivery, type of feeding, medication, 
stress and infections[15]. The critical gut microbiota 
developmental period occurs in parallel to growth, 
maturation and sprouting of neurons in the young 
brain. In fact, childhood and adolescence represent 
the most dynamic and vulnerable periods for both gut 
microbiota composition and neuronal development[16]. 
Furthermore, although the symbiotic link between 
the host and the microbiota seems to be established 
early in life, the gut microbiota composition may still 
experience changes in adulthood despite its greater 
resilience to the effect of detrimental environmental 
factors. Likewise, it is also well recognized that ageing 
is associated with reduced microbial diversity and that 
healthy ageing correlates with a diverse microbiota[17]. 
Furthermore, research shows that as we age there is a 
decline in microbiota complexity parallel to a decrease 
in neuronal complexity and, altogether, those changes 
may lead to an increased risk of neurodegenerative 
disorders[18]. Nowadays, it is well recognized that the 
onset of most of the neuropsychiatric disease really 
often is close to a period where the gut microbiota 
is more unstable and, therefore, at risk of suffering 
microbiota alterations. Despite these findings, there is 
currently a need for longitudinal studies in humans to 
assess the impact of the gut microbiota dynamics on 
the maintenance or decline of neurocognitive function 
and to understand to what extent results in animal 
models can be generalized to humans[19].
In this review, first we summarize the current 
evidence for a role of the gut microbiota in brain 
development and function, and also summarize the 
state of the art on the different mechanisms involved. 
Thereafter, we provide an update on research into 
specific neuropsychiatric disorders. We also refer to 
the different stages of gut microbiota development 
and maturation, identifying the periods where the 
gut microbiota is more unstable and, therefore, at 
greater risk of suffering microbiota alterations due 
to exposure to stressors. Lastly, we briefly highlight 
different microbiome intervention strategies that 
might be implemented to improve the management of 
psychiatric diseases. 
MICROBIOTA, BRAIN DEVELOPMENT, 
FUNCTION AND BEHAVIOR 
To investigate the role of the gut microbiota in the gut-
brain axis, numerous approaches have been taken 
using animal models, including the study of microbiota 
deficient animals, known as germ-free (GF) mice, 
and of animals treated with antibiotics or with specific 
bacterial species. Such studies have provided new 
insights into how the microbiota is involved in regulating 
brain development and function (Table 1)[20,21]. 
Recently, different studies using GF mice have 
demonstrated that animals completely lacking 
microbiota have impaired social behavior, as well as 
other types of behaviors such as anxiety and stress 
response[22-24]. Furthermore, it has been observed 
that certain behaviors induced by the absence of gut 
microbiota correlate with neurochemical changes in the 
brain[24]. Said studies have also shown crucial changes 
in multiple neurotransmitters and their receptors in 
different brain regions of GF mice. Moreover, the ability 
to transfer behavioral traits using fecal microbiota 
transplantation has also been demonstrated, suggesting 
that some microbiota changes could be rather a cause 
than a consequence of behavioral alterations[25]. 
Recent data obtained using GF animals have shown 
that neurogenesis, a process that plays a critical role in 
modulating learning and memory, is also regulated by 
the microbiome[26]. Furthermore, the gut microbiota is 
reported to modulate structural and functional changes 
in the amygdala, a critical brain area for social and 
fear-related behaviors, which are associated with a 
variety of neuropsychiatric disorders[27]. 
Another aspect of neurodevelopment shown to 
be critically regulated by the microbiome is prefrontal 
cortical myelination[28]. A recent study also showed that 
depletion of the gut microbiota as of early adolescence 
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Table 1  Preclinical evidences of the role of gut microbiota on behavior
Germ-free (GF) mice have shown impaired social behavior[39]
GF mice have displayed exaggerated stress response[21] and differences in anxiety-like behavior[22,23]
GF mice have showed crucial changes in multiple neurotransmitters and their receptors in different brain regions[23]
GF animals have exhibited an impaired neurogenesis[25] and structural and functional changes in the amygdala[26]
GF mice have shown prefrontal cortical hypermyelination[27]
Microglial function impaired in GF animals is rescued by the oral treatment with short chain fatty acids[11]
Gut microbiota has been shown to modulate brain-derived neurotrophic factor, oxytocin and vasopressin brain levels[20]
Different probiotic preparations for administration to rats and mice have shown to achieve a reduction in anxiety-like and depressive-like behaviors[6,58]
Cenit MC et al . Microbiota and neuropsychiatric disorders
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have been identified by which also brain can influence 
the gut microbiota composition[7]. Results of animal 
studies show that stress and emotions cause the 
brain to influence the microbial composition of the gut 
through the release of hormones or neurotransmitters, 
which influence gut physiology and alter the habitat 
of the microbiota, resulting in preferential growth of 
certain communities. Indeed, host stress hormones 
such as noradrenaline might influence bacterial gene 
expression or signaling between bacteria, and this 
might change the microbial composition and activity 
of the microbiota. In addition, the microbiota has 
a substantial impact on the metabolomics profile 
of the host. It is important to highlight that a large 
array of crucial molecules with neuroactive functions 
is produced by microbes[7]. Nowadays it is clear that 
certain bacteria are strain­specifically able to produce 
different essential neurotransmitters and specific 
neuromodulators. Indeed, several neurotransmitters 
such as gamma-aminobutyric acid (GABA), serotonin, 
catecholamines and acetylcholine are produced by 
bacteria, some of which are inhabitants of the human 
gut. Indeed, researchers report that Lactobacillus 
spp. and Bifidobacterium spp. produce GABA[29]; 
Escherichia spp., Bacillus spp. and Saccharomyces spp. 
produce noradrenalin; Candida spp., Streptococcus 
spp., Escherichia spp. and Enterococcus spp. 
produce serotonin; Bacillus spp. produce dopamine; 
and Lactobacillus spp. produce acetylcholine[6]. 
Neurotransmitters secreted from bacteria in the 
intestinal lumen may induce epithelial cells to release 
molecules that, in turn, have the ability to modulate 
neural signaling within the enteric nervous system 
in mice alters their behavior and significantly reduces 
brain-derived neurotrophic factor (BDNF), oxytocin and 
vasopressin expression in the adult brain[21]. 
Very recently it has been demonstrated that 
the maturation and activation of microglia, the ma-
crophages of the brain crucial for maintaining brain 
tissue homeostasis, are also regulated by the gut 
microbiota[11]. The same study demonstrated that 
treatment with microbial-produced short-chain fatty 
acids (SCFAs) could rescue microglial function impaired 
in GF animals[11]. In addition, various studies have 
shown that probiotic administration to healthy rats 
and mice can alter behavior, achieving a reduction in 
anxiety-like and depressive-like behaviors and thus 
highlighting the beneficial effects of probiotics on stress­
related behaviors[6]. All these findings indicate that 
probiotics may have broader therapeutic applications 
than previously considered, particularly in the area of 
anxiety and depression[6]. 
GUT MICROBIOTA MECHANISMS 
MODULATING BRAIN DEVELOPMENT 
AND FUNCTION
Recent studies have provided insights into the 
possible pathways and mechanisms that connect the 
microbiota to the brain. In fact, recent evidence largely 
suggests that there are several mechanisms by which 
microbiota may modulate brain development, function 
and behavior including immune (cytokines), endocrine 
(cortisol) and neural (vagus and enteric nervous system) 
pathways (Figure 1). Likewise, different mechanism 
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Figure 1  Schematic representation of the mechanisms involved in the relationship between microbiota and brain development and function: Cytokine 
balance and microglia activation (immune pathway), cortisol (endocrine pathway) and vagus and enteric nervous system (neural pathway). The axis 
plays an important role in homeostasis and has been linked to several disorders. Altered gut microbiota composition enhances the risk of neurodevelopmental and 
neurodegenerative disorders possibly from microbiota-derived products such as small chain fatty acids and neurotransmitters. HPA: Hypothalamic-pituitary-adrenal.
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and subsequently control brain function and behavior. 
Various bacterial strains have also been shown to 
mediate behavioral effects via the vagus nerve in some 
animal studies although vagotomy does not seem 
to mediate all microbiota-mediated effects on brain 
function and behavior[30].     
Tryptophan is an essential amino acid precursor 
to many biologically active molecules, including the 
neurotransmitter serotonin and metabolites of the 
kynurenine pathway. Only around 5% of systemic 
tryptophan is metabolized into serotonin and the 
rest is metabolized along the kynurenine pathway. 
This depends on the expression of two enzymes, 
indoleamine 2,3-dioxygenase, which is found in all 
tissues, and tryptophan 2,3-dioxygenase, which is 
localized within the liver. The activity of both enzymes 
is strongly controlled by inflammatory mediators 
such as cytokines and corticosteroids. The increased 
activation of these two enzymes could induce serotonin 
depletion and depressive mood. Furthermore, the 
downstream metabolites of the kynurenine pathway 
are neuroactive metabolites, which can also modulate 
neurotransmission. In addition, the oral ingestion of 
Bifidobacterium infantis led to increased levels of the 
serotonin precursor, tryptophan, in the plasma of rats, 
suggesting that this specific strain may be a potential 
antidepressant. Other studies have also demonstrated 
the effect of the gut microbiota on the levels of other 
metabolites related with tryptophan metabolism[31]. 
Other important molecules, which are produced in 
the colon by microbial fermentation of dietary fiber, 
are SCFAs such as butyrate, acetate and propionate. 
SCFAs are known to have neuroactive properties; 
for instance, the administration of a high dose of 
propionate in rats induced a neuroinflammatory 
response and behavioral alterations related with 
neurodevelopmental disorders[32]. Propionate is also a 
common preservative in food products that has been 
demonstrated to exacerbate autism spectrum disorder 
symptomatology. Moreover, butyrate decreases 
depressive-like behavior with parallel changes in 
histone deacetylation and BDNF expression. SCFAs 
also regulate the gut immune system and this may 
have consequences on the central nervous system. 
As mentioned above, the maturation and activation 
of microglia is also regulated by the gut microbiota[11] 
and oral treatment with microbial produced SCFAs can 
rescue microglial function impaired in GF animals[11]. 
However, it is still unclear whether SCFAs produced in 
the gut can cross the blood-brain barrier.
EPIGENETICS, GUT MICROBIOTA AND 
NEUROLOGICAL CONDITIONS
It is currently well recognized that there are many 
changes in gene expression not caused by variations 
in sequence or genotype. Those changes are rather 
triggered by epigenetic modifications, such as 
methylation, acetylation or non-coding RNAs (ncRNAs), 
which modulate chromatin remodeling and the final 
translation of coding mRNA into proteins. Several 
types of epigenetic-modifying enzymes together with 
ncRNAs are involved in epigenetic regulation and have 
been demonstrated highly sensitive to environmental 
changes. Therefore, epigenetic modifications associated 
to many diseases have been recognized as possible 
pieces missing in the puzzle linking the human genome, 
environment and phenotype development[33]. Epigenetic 
mechanisms are currently known to be involved in 
neurogenesis, neuronal plasticity, learning and memory, 
and in disorders such as depression, addiction, 
schizophrenia and cognitive dysfunction[3,34]. Many of 
the environmental factors apparently playing a crucial 
role in the etiology of neuropsychiatric disorders might 
be related with the risk of developing the condition 
through epigenetic mechanisms. 
Changes in histone modifications and DNA methy­
lation have been found at the promoters of genes 
involved in neuropsychiatric conditions[3]. For instance, 
chromatin remodeling at the BDNF gene promoter 
has been associated with neuronal activity and stress 
and likely affects many more genes involved in brain 
function and behavior[35]. In fact, there is now a great 
deal of evidence for the role of epigenetic regulation 
in shaping brain function and behavior, even though 
the underlying molecular mechanisms by which 
epigenetics might be leading to the behavioral and 
biochemical alterations observed in neuropsychiatric 
disorders are still not well understood[36]. 
Gut microbiota has been shown to impact host gene 
expression by modulating epigenetic processes which 
are highly dynamic and reversible[33]. Therefore, it is 
tempting to speculate that modulating the microbiota 
will enable us to shape our epigenome in the near 
future. Indeed, the methylation levels of specific genes 
involved in metabolism and inflammatory responses 
have been associated with gut microbiota profiles[37]. 
Furthermore, various studies have described a link 
between microRNAs, a group of small ncRNAs, and 
microbiota[38]. Histone deacetylations by HDACs are 
also critical in epigenomic regulation and are related 
with condensed chromatin and, consequently, the 
inhibition of the gene expression. Indeed, SCFAs have 
the capacity to inhibit HDACs, thus activating the gene 
expression of previously deacetylated genes[33]. 
Aging is associated with profound epigenetic 
changes resulting in alterations in gene expression 
and also with a wide range of human disorders, 
including neurodegenerative diseases. Therefore, the 
reversibility of epigenetic changes that occur as a 
hallmark of aging offers exciting opportunities to treat 
age-related diseases[39]. 
GUT MICROBIOTA AND 
NEUROPSYCHIATRIC CONDITIONS 
So far many evidences derived from multiple studies 
performed in both animal models and humans have 
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strongly suggested a link between gut microbiota 
and development and/or manifestation of different 
neuropsychiatric conditions (Table 2).
Microbiota and impairment of social behavior (autism), 
schizophrenia and attention deficit hyperactivity 
disorder 
Studies using GF mice have demonstrated that animals 
completely lacking microbiota exhibit deficiencies in 
social behavior. In particular, John Cryan’s research 
team examined the behavior of GF mice in the three-
chamber test and observed that GF mice spent as 
much time with the familiar as with the novel mouse 
in contrast to the behavior of conventionally colonized 
mice, which spent more time with the novel than the 
familiar mouse[40]. They also observed that GF mice 
spent longer with an object or an empty chamber than 
with another mouse, which is considered abnormal 
behavior for a sociable animal. Research has also 
demonstrated that colonization of the GF mice partially 
normalizes these behavioral impairments[40].
Oxytocin is well known to influence social behavior[41] 
and evidence indicates that its levels are closely 
regulated by the gut microbiota[42]. In fact, last year 
Desbonnet et al[21] showed that depletion of the gut 
microbiota as of early adolescence reduces oxytocin 
expression in the adult brain. Furthermore another 
recent study demonstrated that a single probiotic 
bacteria (a strain of the species Lactobacillus reuteri) 
can modulate oxytocin levels and reverse autism-
related behavior, raising the possibility of influencing 
social behavior by targeting the gut microbiota[42].
Autism spectrum disorder (ASD) is often associated 
with gastrointestinal co-morbidities and recent studies 
have shown changes in the gut microbiota of autistic 
children, including shifts in levels of Bacteroidetes and 
Firmicutes phyla with the abundance of Clostridium, 
establishing a strong link between gut microbiota 
and ASD[43,44]. Research also reports an increase 
in microbiota diversity associated with autism in 
children with the abundance of Bacteroidetes found 
to be linked with severe autistic cases[44]. Other gut 
commensals found to be altered in autism belong 
to Bifidobacterium, Lactobacillus, Prevotella and 
Table 2  Current evidences linking gut microbiota to neuropsychiatric disorders
Autism
   Increase in microbiota diversity is associated with autism[43]
   Abundance of Bacteroidetes has found to be linked with severe autistic cases[43]
   Increase in short chain fatty acids has been found in fecal samples from autistic children[44]
   A specific strain of the species Lactobacillus reuteri has shown to modulate oxytocin levels and reverse autism-related behavior[41]
Schizophrenia
   Dopamine, the key neurotransmitter associated with schizophrenia pathophysiology, is produced by components of the microbiota[53] 
   Increased gastrointestinal inflammation is associated with schizophrenia[53]
   Intake of antibiotics is associated with the risk of schizophrenia[54] 
Attention deficit hyperactivity disorder  
   The risk of developing ADHD has been suggested to be associated with many perinatal risk factors, including delivery mode, gestational age, type of 
   feeding, maternal health and early life stressors, all of them linked to gut microbiota alterations[56] 
   Dietary components modulating gut microbiota may influence ADHD development or symptoms[56]
Depression
   Increase in gut microbiota alpha diversity is associated with depression[59,63]
   Lower numbers of Bifidobacterium and Lactobacillus have been found in individuals with depression[60]
   Increases in the genus Eggerthella, Holdemania, Gelria, Turicibacter, Paraprevotella and Anaerofilm, and reductions in Prevotella and Dialister have been 
   found in individuals with depression[61]
   A negative correlation between Faecalibacterium spp. and severity of depressive symptoms has been reported[61]
   Role of diet on depression onset is suggested (Mediterranean diet seems to protect, whereas Western diet seems to be associated with an increased 
   risk)[64]
   Different strains of Lactobacillus rhamnosus, Lactobacillus helveticus, Bifidobacterium longum, Bifidobacterium breve and Bifidobacterium infantis have been 
   shown to attenuate depression and anxiety-related behavior in rodents[58]
   A probiotic combination (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) has proven effective in increasing the subject’s resilience to 
   stress in humans[57]
Parkinson’s disease
   Alterations in bowel function, mainly constipation, often precede the onset of motor symptoms associated with PD[76]
   Reduction in the levels of Prevotellaceae has been found in PD patients[80]
   Positive correlation between levels of Enterobacteriaceae and the severity of postural instability and gait difficulty was proven in PD patients[80]
   Reduction in short chain fatty acids[78] and butyrate-producing bacteria (Blautia, Coprococcus, Faecalibacterium spp and Roseburia)[79] were found in fecal 
   samples from PD patients
   GF mice overexpressing human α-synuclein (αSyn) display reduced microglia activation, αSyn aggregates and motor deficits (treatment with short 
   chain fatty acids restored all major features of PD in GF mice)[77] 
   Gut microbiota transfer from PD patients into GF mice overexpressing human α-synuclein (αSyn) enhances physical impairments whereas gut 
   microbiota transfer from healthy human donor does not enhances those deficiencies[77]
Alzheimer’s disease  
   Risk factors for AD such as metabolic syndrome, type 2 diabetes and obesity are associated with gut microbiota alterations[86,87] 
   Gut microbiota seems to be involved in the accumulation of amyloid plaques according to the results of a study using a mouse model of AD[88]
AD: Alzheimer’s disease; PD: Parkinson’s disease; ADHD: Attention deficit hyperactivity disorder.
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Ruminococcus genera[44] although these associations 
do not necessarily imply causality. In addition, a 
significant increase in SCFAs in fecal samples from 
autistic children has been recorded, providing a 
further indication for a role of an altered microbiota 
composition or function in this neurodevelopmental 
disorder[45]. However, the role of SCFAs in ASD is 
not fully understood. For instance, administration 
of butyrate has been shown to improve repetitive 
symptoms in a murine model of ASD[46] whereas intra 
cerebroventricular infusions of propionic acid induces 
autistic-like behaviors in rats[47], thus suggesting SCFAs 
play differential roles in mediating ASD behavior. 
Therefore, further research is warranted to delve 
further into the role of SCFAs in autism.
In humans, prenatal exposure to the mood sta-
bilizer valproate is a major risk-factor for autism[48] 
and de Theije et al[49] have shown that the autism-
like behavioral changes that occur in mouse models 
of valproate exposure are coincident with changes in 
microbiota composition. 
In addition, maternal obesity is associated with 
neurodevelopmental disorders in offspring, including 
autism spectrum disorder[50] and, in line with this 
observation, mice with induced obesity by a maternal 
high-fat diet (MHFD) show social behavioral deficits 
due to alterations in the gut microbiota[51]. Buffington 
et al[51] recently observed that the diversity of the 
microbiota in MHFD offspring was reduced, showing a 
remarkable reduction in Lactobacillus spp. compared 
with the abundance found in the offspring of animals 
from mothers on a regular diet. Furthermore, it was 
demonstrated that treatment with a Lactobacillus 
reuteri strain not only augmented levels of oxytocin, 
improving social behavior, but also ameliorated synaptic 
dysfunction in MHFD offspring[51].
Schizophrenia is another complex heterogeneous 
behavioral disorder characterized by abnormal social 
behavior, often associated with additional mental 
health problems such as anxiety disorders and major 
depression[52]. To date the genomic analysis of schizo-
phrenia has been limited, with the replicated genetic 
findings representing just a fraction of schizophrenia 
heritability[53]. Furthermore, there is evidence for the 
important role that different environmental factors 
play in its development. In fact, several epigenetic 
mechanisms, in particular methylation of genes 
involved in neurotransmission, histone modifications 
and the action of ncRNAs, may also predispose 
individuals to schizophrenia. There are indications, such 
as the fact that dopamine, the key neurotransmitter 
associated with schizophrenia pathophysiology and 
treatment, is produced by microbes, and the in-
creased gastrointestinal inflammation associated 
with schizophrenia, which strongly suggest that gut 
microbiota are involved in the risk of development 
schizophrenia or its manifestations[54]. In addition, 
several studies have found an association between 
the intake of antibiotics and an increased incidence of 
psychiatric disorders such as schizophrenia, perhaps 
due to alterations in the microbiota[55]. However, to 
date there are not any published studies investigating 
the role of the gut microbiome in schizophrenia. 
Attention deficit hyperactivity disorder (ADHD) 
is a neurodevelopmental disorder characterized 
by inappropriate levels of hyperactivity, difficulty 
in controlling behavior and/or attention problems. 
Although ADHD is currently one of the most frequently 
studied disorders in children and adolescents, the 
exact mechanisms that predispose individuals are still 
unknown, though both genetic and environmental 
factors seem to be involved[56]. Various factors 
associated with the risk of developing ADHD and/or 
linked to different ADHD manifestations have also 
been linked to shifts in gut microbiota composition, 
suggesting a link between the microbiota and the 
disorder. In addition, evidence from preliminary human 
studies suggests that dietary components modulating 
gut microbiota may also influence ADHD development 
or symptoms. Therefore, recently, after reviewing the 
literature, we argue[57] that genomic studies in ADHD 
should include studies of the gut microbiota. 
Microbiota, stress response and depression
Most organisms are equipped with biological machinery 
able to muster a defensive response to stressful stimuli. 
In response to stress, the hypothalamic-pituitary-
adrenal (HPA) axis is activated and corticosterone 
releasing factor (CRF) is released from paraventricular 
neurons of the hypothalamus. CRF stimulates the 
release of adrenocorticotrophic hormone (ACTH) 
from the anterior pituitary, which in turn induces the 
synthesis and release of glucocorticoids from the 
adrenal cortex: cortisol in humans and corticosterone 
in animals. Studies in GF mice have revealed that the 
microbiota influences the development of the HPA 
axis and thus the stress response. Animals raised in 
a sterile environment from birth exhibit inflated HPA 
axis activity with elevated ACTH and corticosterone 
levels in response to a stressor[22]. Interestingly, HPA 
axis activity is normalized after colonization with 
commensal bacteria from control mice[25]. 
Although studies investigating the effects of prebiotic 
or probiotic supplements on stress behavior in humans 
are limited, they indicate the role of gastrointestinal 
microbiota in stress and emotional responses. Likewise, 
a probiotic combination (Lactobacillus helveticus R0052 
and Bifidobacterium longum R0175)[58] and a prebiotic 
(galactooligosaccharide)[59] have proven effective 
in increasing the subject’s resilience to stress and 
improved emotional responses in healthy subjects. 
Depression is a stress-related mood disorder 
associated with a disrupted HPA axis, and evidence 
suggests that the gut microbiota play a key role in 
modulating depression[60]. In fact, an increase in alpha 
diversity of the gut microbiota has been reported in 
individuals with depression compared to a healthy 
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control group. Furthermore, patients with depression 
show significantly lower numbers of Bifidobacterium 
and Lactobacillus compared to control subjects[61]. In 
addition, a more recent study shows that patients with 
major depression have altered microbiota compared 
to normal subjects, with a significant increase in the 
genus Eggerthella, Holdemania, Gelria, Turicibacter, 
Paraprevotella and Anaerofilm, whereas reductions 
in Prevotella and Dialister were observed[62]. Another 
recent study also reported a negative correlation 
between Faecalibacterium spp. and the severity of 
depressive symptoms[62]. Moreover, researchers 
have demonstrated that when the microbiota from 
patients with major depression is transferred to 
microbiota-depleted animals, the behavioral and 
physiological features characteristic of depression are 
also transferred, supporting a link between dysbiotic 
microbiota and depression[63]. A recent study published 
in Science reported a correlation between a more 
diverse gut microbiota composition and depression 
in humans after investigating the gut microbiomes 
of 1135 participants from a Dutch population cohort 
using deep sequencing[64]. 
Different diets have been suggested to have 
either positive or negative effects on depression. 
For instance, a Western diet seems to be associated 
with an increased risk of depression, whereas the 
Mediterranean diet seems to reduce the onset of 
depression. Furthermore, studies in human and animal 
models have shown an association between depletion 
of omega-3 polyunsaturated fatty acids and major 
depression, suggesting the role of diet in depression 
onset[65].
Different probiotic treatments have displayed 
efficacy in the reduction of depressive-like behaviors 
in animal models. For instance, administration of a 
probiotic cocktail comprising of Lactobacillus rhamnosus 
and Lactobacillus helveticus strains have been shown 
to ameliorate depressive-like behavior and normalize 
corticosterone levels in a maternal-separation animal 
model. Moreover, administration of Lactobacillus 
rhamnosus reduced depression and anxiety-related 
behavior. Also there is evidence for the association 
between different strains of the genus Bifidobacterium 
and potential antidepressant-like behavior in animals. 
Treatment with a strain of Bifidobacterium infantis 
attenuated depression, showing increased mobile 
episodes during the forced swim test in maternally 
separated rats. A similar effect was also observed with 
strains of Bifidobacterium longum and Bifidobacterium 
breve on depression and anxiety-related behavior in 
rodents[60]. 
Gut microbiota and neurodegenerative conditions
Over a century ago, the Nobel Prize Elie Metchnikoff 
already suggested that the microbial communities 
within the gastrointestinal tract had an influence 
on human health. The Russian scientist Metchnikoff 
observed that people lived longer in parts of Bulgaria 
and Eastern Europe because of the high consumption 
of fermented dairy products containing lactic acid 
bacteria, and suggested that complementing the diet 
with lactic acid bacteria would have health benefits, 
including longevity[66]. The finding that germ-free 
mice live longer than their conventionalized controls 
was also reported many years ago[67,68], supporting a 
link between microbiota and senescence. Nowadays, 
we know that the gut microbiota undergoes a dy-
namic change during aging[69]. It is of interest that 
bifidobacteria numbers decrease with age, while those 
of clostridia increase[70]. Age-related gut microbiota 
composition changes have also been correlated with 
health outcomes in the elderly, such as frailty[71], with 
microbial diversity being an important feature linked 
to health maintenance as we age[18]. However, major 
shifts in diet of the elderly could partly be responsible 
for the dramatic changes in microbiota composition 
and their association with health-relate outcomes[72]. 
This also suggests there is a chance of redressing the 
balance by dietary-based interventions in the elderly. 
Aging can weaken gastrointestinal barrier function 
and promote a proinflammatory phenotype involving 
the microbiota[73]. Another consequence of ageing is 
the progressive leakiness of the blood-brain-barrier 
(BBB), whose integrity also seems to be dependent on 
gut microbiota composition[74]. SCFAs produced by gut 
microbiota components are considered key metabolites 
mediating such effects. Stress is one of the lifestyle 
factors that can negatively impact BBB permeability[75] 
and accelerate the “inflamm­aging” processes linked to 
age-related diseases[76]. Therefore, understanding how 
the gut microbiota or their components influence such 
processes is now worthy of attention.
Parkinson’s disease (PD) is a neurodegenerative 
disorder that represents a growing health concern in 
the elderly. It is characterized by neuroinflammation 
and loss of midbrain dopaminergic neurons, as well 
as by a characteristic pattern of abnormal movements 
with a number of non-motor symptoms[77]. It has 
also been observed that alterations in bowel function, 
mainly constipation, often precede the onset of 
prototypical motor symptoms associated with PD. 
While genetics plays an important role in the risk 
of developing the disease, environmental factors 
and gene-environment interactions also contribute 
to the risk for developing the disorder[78]. In fact, 
evidence suggests that gut microbiota is an important 
environmental factor related to the risk of PD[78-81]. 
Interestingly, a recent study sequenced the gut 
microbiota in patients with PD and controls[81]. The 
authors of this study compared 72 patients and 72 
matched controls, confirming a major reduction in 
the levels of Prevotellaceae in PD patients. They also 
observed and described a positive correlation between 
the levels of Enterobacteriaceae and the severity of 
postural instability and gait difficulty[81], suggesting the 
role of the gut microbiota in the PD phenotype. Another 
study showed that at the taxonomic level of genus, 
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putative “anti-inflammatory” butyrate-producing 
bacteria from the genera Blautia, Coprococcus, and 
Roseburia were significantly more abundant in feces 
of controls than PD patients. On the other side, in 
this study it was also reported that bacteria from the 
genus Faecalibacterium were significantly found more 
abundant in the mucosa of controls than PD patients, 
whereas putative “pro­inflammatory”. Proteobacteria of 
the genus Ralstonia were significantly more abundant 
in mucosa of PD patients than controls[81]. 
Intriguingly, another recent study confirmed the 
recently reported association between PD and the 
reduced abundance of butyrate-producing bacteria, and 
also demonstrated a reduction in the relative SCFAs 
concentration in PD compared with the abundance 
observed in controls, suggesting a role for SCFAs 
in PD[78]. However, prospective longitudinal studies 
in subjects at risk of PD are still required to further 
elucidate the causal role of the gut microbiota and 
microbial products in the development of PD and its 
manifestations. 
Very recently it has been reported that gut microbiota 
is involved in motor deficits and neuroinflammation 
in a model of PD, suggesting that the changes in 
the gut microbiota represent a risk factor for PD[78]. 
This study revealed that under GF conditions, or 
antibiotic-related bacterial depletion, transgenic 
animals overexpressing human α-synuclein (αSyn) 
(an abundant protein in the human brain involved in 
neurotransmitter release) displayed reduced microglia 
activation, αSyn aggregates and motor deficits 
(neuropathological features of PD) compared to 
animals with a complex microbiota. Conversely, they 
showed that treatment with SCFAs restored all major 
features of PD in GF mice. Furthermore, this study 
demonstrated that transplanting gut microbiota from 
PD patients into genetically susceptible mice (αSyn-
overexpressing mice) enhances physical impairments 
when compared to microbiota transplant from healthy 
human donors[78]. 
Alzheimer’s disease (AD) and vascular dementias 
are the most common causes of cognitive decline in 
ageing populations in Western countries[82]. The deficit 
in synaptic plasticity is one of the many changes 
occurring with age. Specifically, the typical model 
of plasticity shows a reduction in the hippocampus 
long-term potentiation (LTP) of the middle-aged, but 
most dramatically in aging rats[83]. A recent study has 
investigated whether the age-related deficit in LTP 
might be attenuated by changing the composition of 
intestinal microbiota with VSL#3, a probiotic mixture 
comprising 8 Gram-positive bacterial strains. The 
study showed that the age­related deficit in LTP was 
attenuated in VSL#3-treated aged rats and this was 
accompanied by a modest decrease in markers of 
microglial activation and an increase in expression 
of BDNF and synapsin[84]. However, although these 
findings support the fact that intestinal microbiota can 
be manipulated in order to positively impact neuronal 
function modulating microglial activation, at the moment 
we still need to be cautious and to investigate further 
the different probiotics that could be used to modify 
the microglial maturation and function.
Surprisingly, so far there is a lack of detailed 
analyses of the microbiota of patients with AD[85]. 
However, in metabolic syndrome, type 2 diabetes 
and obesity, which are risk factors for AD[86], there 
is an alteration in the gut microbiota[87,88]. More 
recently, a research study using a mouse model of 
AD has implicated the microbiota in the accumulation 
of amyloid plaques[89], and there is also evidence 
suggesting that gut microbiota might be directly linked 
to dementia pathogenesis by triggering metabolic 
diseases and low-grade inflammation[90]. Different 
mechanisms may explain the link between gut 
microbiota alterations in obesity and T2D and the 
development of AD. For example, different studies 
have indicated that an altered gut microbiota linked 
to obesity increases intestinal permeability and 
contributes to systemic inflammation leading to insulin 
resistance and T2DM[91]. In turn, insulin resistance 
and T2DM is a risk factor for development of AD. 
Furthermore, the vascular effects of obesity and T2D, 
related to changes on the gut microbiota, also appear 
to play an important role in the development of AD[92]. 
A leading hypothesis on the pathophysiology of AD is 
the mis-metabolism of amyloid precursor protein. The 
Aβ peptide is derived from amyloid precursor protein 
by sequential cleavages of different proteases. The 
activity of these proteases involved in the generation 
of Aβ peptide is highly regulated by the inflammation, 
being the latter modulate as already mentioned by 
the gut microbiota. In fact, BACE1 enzyme is essential 
for the generation of β-amyloid and Interleukin 1β, 
considered as a risk factor for AD development, has 
been observed to aggravate plaque formation by 
induction of BACE1 expression[93]. 
However, although it has been suggested that 
alterations on gut microbiota observed in diabetes and 
obesity may be linked to the risk of developing AD, 
there is a need of further work to elucidate the specific 
gut’s microbes and the mechanisms involved in the 
link between obesity, T2D and AD.
Dysregulation of normal microglial functions such 
as synaptic pruning and regulation is increasingly found 
to be implicated in diseases associated with cognitive 
deficits[12,94]. Microglia cells are also essential for 
clearance of debris, plaques and aggregates, thereby 
playing a fundamental role in neurodegenerative 
amyloid disorders, including Alzheimer’s, Huntington’s 
and Parkinson’s diseases, each associated with a distinct 
amyloid protein. Therefore, targeting dysregulated 
microglial functions represents a therapeutic opportunity 
for treating these disorders[95,96]. Although the mecha-
nisms that ultimately lead to neurodegeneration are 
different in each neurodegenerative disease, chronic 
inflammation that may be modulated by the gut 
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microbiota is typically a prominent feature in the 
progressive nature of neurodegeneration[12].
CONCLUSION
It is becoming evident that brain development and 
function are dependent on the diversity and structure 
of the gut microbiota and may, therefore, influence 
mental health. This hypothesis is based mainly on 
animal trials and a few observational human studies 
associating gut microbiota alterations with mental 
disorders, including depression, autism and PD. 
This notion has been further supported by recent 
transplantation experiments where the gut microbiota 
has been shown to transfer a behavioral phenotype 
or the disease features to the recipient animal, 
providing stronger evidence for a causal relationship. 
However, longitudinal studies in humans are still 
needed to investigate whether the gut microbiota 
changes in subjects with different neuropsychiatric 
disorder can contribute to disease onset and the role 
of other interacting factors such as the diet. So far 
various communication routes between the microbiota 
and brain have been identified, including immune, 
endocrine and neural pathways. Thus, interventions 
with pro and pre-biotics in animal models have shown 
that the microbiota could play a role in mental health 
by regulating inflammatory and endocrine secretions, 
synthetizing neuroactive compounds and interacting 
with the vagal nerve. Greater understanding of the 
precise underlying mechanisms is required to develop 
a clear rationale for conducting microbiota-based 
interventions in humans. In particular, inflammation 
seems to be a critical pathophysiological feature of 
mental disorders and, therefore, a potential target 
for microbiota-based interventions. Nonetheless, 
further knowledge is needed on how microbiota 
signals generated in the gut can impact on microglial 
activation and neuroinflammation.
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